0 stringlengths 12 494 | embeddings listlengths 384 384 |
|---|---|
l o s sa n dg u i d e di nt h er a n g eo fa v a i l a b l e\ntreatment options, as discussed in thesections below. Shared decision-makingshould be used when counseling onbehavioral changes, intervention choices,and weight management goals.\nNUTRITION, PHYSICAL ACTIVITY,\nAND BEHAVIORAL THERAPY\nRecommendations\n8.7Nut... | [
-0.0028933691792190075,
0.045880015939474106,
-0.03576112911105156,
0.053841590881347656,
-0.07088306546211243,
0.06785546243190765,
0.031581979244947433,
0.0377018116414547,
-0.06455356627702713,
0.03063066303730011,
0.032923340797424316,
0.003135044826194644,
-0.06089380383491516,
0.0250... |
Recommendations\n8.7Nutrition, physical activity, and\nbehavioral therapy to achieve and\nmaintain $5% weight loss are rec-\nommended for people with type 2diabetes and overweight or obesity. B\n8.8a Interventions including high fre-\nquency of counseling ( $16 sessions | [
-0.01599564403295517,
0.01727048121392727,
0.02627633884549141,
0.09953504055738449,
-0.07745857536792755,
0.0773589238524437,
0.06260887533426285,
0.01145109161734581,
-0.05869942530989647,
0.018140623345971107,
-0.04629673436284065,
0.00015324444393627346,
-0.09457384049892426,
0.0065962... |
quency of counseling ( $16 sessions\nin 6 months) with focus on nutritionchanges, physical activity, and be-havioral strategies to achieve a\n500– 750 kcal/day energy defi cit have\nbeen shown to be bene ficial for weight\nloss and should be considered whenavailable. A\n8.8b Consider structured programs de-\nlivering beh... | [
-0.0203628558665514,
0.06802239269018173,
-0.027371209114789963,
0.09024877846240997,
-0.1321934312582016,
0.04835600405931473,
0.044092439115047455,
0.0010841205948963761,
-0.03941277042031288,
-0.005999802611768246,
0.0012051002122461796,
-0.08577282726764679,
-0.0500224269926548,
-0.008... |
livering behavioral counseling (face-to-\nface or remote) to address barriers to\naccess. E\n8.9Nutrition recommendations should\nbe individualized to the person’ sp r e f -\nerences and nutritional needs. Use nu-tritional plans that create an energy\ndeficit, regardless of macronutrient\ncomposition, to achieve weight ... | [
0.003271197434514761,
0.03375832736492157,
-0.05766623094677925,
0.051923323422670364,
-0.05950336158275604,
0.06961243599653244,
-0.022276567295193672,
0.08600419759750366,
-0.1086466833949089,
-0.04782305285334587,
0.01650390215218067,
-0.08745580911636353,
-0.07418578118085861,
0.004442... |
composition, to achieve weight loss. A\n8.10 When developing a plan of care,\nconsider systemic, structural, and so-cioeconomic factors that may impactnutrition patterns and food choices,\nsuch as food insecurity and hunger,\naccess to healthful food options, cul-tural circumstances, and other social\ndeterminants of h... | [
0.027683641761541367,
0.06022152304649353,
0.01310179103165865,
0.07919241487979889,
-0.05366948992013931,
0.10704636573791504,
0.010471941903233528,
0.06407725065946579,
-0.04831109941005707,
-0.0326475091278553,
0.05943163111805916,
-0.04639361798763275,
-0.06383950263261795,
-0.07537961... |
determinants of health. C\n8.11a For those who achieve weight\nloss goals, long-term ( $1y e a r )w e i g h t\nmaintenance programs are recom-mended, when available. Effective pro-\ngrams provide monthly contact andsupport, recommend ongoing monitor-\ning of body weight (weekly or more | [
-0.021848628297448158,
0.047596294432878494,
-0.021573424339294434,
0.030195867642760277,
-0.030701005831360817,
0.08464603871107101,
0.0438648983836174,
0.07912227511405945,
-0.07085410505533218,
0.0010548371355980635,
0.021455951035022736,
-0.07369040697813034,
-0.059663236141204834,
-0.... |
ing of body weight (weekly or more\nfrequently) and other self-monitoringstrategies, and encourage regular phys-\nical activity (200 –300 min/week). A\n8.11b For those who achieve weight\nloss goals, continue to monitor prog-\nress periodically, provide ongoing sup-\nport, and recommend continuing | [
-0.020868968218564987,
0.05068472772836685,
0.009995091706514359,
0.04176511615514755,
-0.02575346641242504,
0.028065189719200134,
0.03475209325551987,
0.016614260151982307,
-0.07377522438764572,
-0.04089582338929176,
-0.012432721443474293,
-0.0440593883395195,
-0.05278123915195465,
0.0178... |
port, and recommend continuing\nadopted interventions to maintaingoals long term. E8.12 When short-term nutrition inter-\nvention using structured, very-low-\ncalorie meals (800 –1,000 kcal/day) is | [
0.022279031574726105,
0.07834389060735703,
0.026975838467478752,
0.06028524413704872,
-0.11449180543422699,
0.031034570187330246,
-0.052014708518981934,
0.06660351157188416,
-0.07842396199703217,
-0.10390209406614304,
0.0807352215051651,
0.004419068805873394,
-0.04967194050550461,
-0.06102... |
calorie meals (800 –1,000 kcal/day) is\nconsidered, it should be prescribed tocarefully selected individuals by trainedpractitioners in medical settings withclose monitoring. Long-term, compre-hensive weight maintenance strategiesand counseling should be integratedto maintain weight loss. B\n8.13 Nutritional supplement... | [
-0.007534236181527376,
0.06942146271467209,
-0.0013106951955705881,
0.005161625798791647,
-0.06482484936714172,
0.02915831096470356,
0.03948250040411949,
0.030762918293476105,
-0.01884991116821766,
-0.07271376997232437,
0.01883913204073906,
-0.05218786746263504,
-0.027045268565416336,
-0.0... |
8.13 Nutritional supplements have not\nbeen shown to be effective for weightloss and are not recommended. A\nFor a more detailed discussion of life-\nstyle management approaches and rec-\nommendations, see Section 5, “Facilitating\nPositive Health Behaviors and Well-being\nto Improve Health Outcomes. ”For a de- | [
-0.06290808320045471,
0.05674413591623306,
0.0033225647639483213,
0.03760598599910736,
-0.027141740545630455,
0.016171904280781746,
-0.0005239714519120753,
0.07790792733430862,
-0.05645255744457245,
-0.08117039501667023,
0.08205153793096542,
0.04769730567932129,
-0.04323512315750122,
-0.01... |
to Improve Health Outcomes. ”For a de-\ntailed discussion of nutrition interventions,please also refer to “Nutrition Therapy for\nAdults With Diabetes or Pre-diabetes: A\nConsensus Report ”(53).\nLook AHEAD Trial\nAlthough the Action for Health in Diabetes\n(Look AHEAD) trial did not show that the\nintensive lifestyle ... | [
-0.03132764250040054,
0.08496691286563873,
0.026353146880865097,
0.0629349872469902,
-0.0055857133120298386,
0.06503552943468094,
-0.014688373543322086,
0.03816225379705429,
-0.01778748817741871,
-0.031840961426496506,
0.01978803239762783,
0.10696566104888916,
-0.0752963125705719,
-0.09518... |
intensive lifestyle intervention reduced\ncardiovascular events in adults with type 2\ndiabetes and overweight or obesity (41), itdid con firm the feasibility of achieving and\nmaintaining long-term weight loss in peo-\nple with type 2 diabetes. In the intensive\nlifestyle intervention group, mean weight | [
0.03182942420244217,
0.07663369923830032,
0.05087575688958168,
0.06183399632573128,
0.002546977251768112,
-0.01877426728606224,
-0.034387797117233276,
0.10854534059762955,
-0.08993694186210632,
0.0015190955018624663,
-0.0035594371147453785,
0.03163744509220123,
-0.03800617903470993,
-0.017... |
lifestyle intervention group, mean weight\nloss was 4.7% at 8 years (42). Approxi-mately 50% of intensive lifestyle interven-\ntion participants lost and maintained $5%\nof their initial body weight, and 27% lostand maintained $10% of their initial body\nweight at 8 years (42). Participants as-\nsigned to the intensive... | [
0.023700209334492683,
0.07565103471279144,
0.027103012427687645,
0.1254226714372635,
-0.039972975850105286,
0.035302188247442245,
-0.07487514615058899,
0.11690765619277954,
-0.125278502702713,
-0.04029862955212593,
0.07744747400283813,
-0.057406071573495865,
0.008920001797378063,
-0.002693... |
signed to the intensive lifestyle group re-\nquired fewer glucose-, blood pressure-,\nand lipid-lowering medications than those\nrandomly assigned to standard care. Sec-\nondary analyses of the Look AHEAD trialand other large cardiovascular outcome\nstudies document additional weight loss\nbenefits in people with type 2... | [
-0.0316556952893734,
0.06529787182807922,
0.004505939316004515,
0.0582115463912487,
-0.011358908377587795,
0.025596117600798607,
-0.1010630875825882,
0.07039181888103485,
-0.053180817514657974,
-0.03986281529068947,
-0.053489115089178085,
0.059187404811382294,
-0.08481385558843613,
-0.0562... |
benefits in people with type 2 diabetes, in-\ncluding improved mobility, physical and\nsexual function, and health-related quality\nof life (34). Moreover, several subgroups\nhad improved cardiovascular outcomes,\nincluding those who achieved >10%\nweight loss (43).\nBehavioral Interventions\nSignificant weight loss can ... | [
0.015001638792455196,
0.08201829344034195,
-0.009755917824804783,
0.04499835893511772,
-0.055495485663414,
0.04001596197485924,
0.031499721109867096,
0.028382759541273117,
-0.08103872090578079,
-0.019708525389432907,
-0.013311516493558884,
0.0491197407245636,
-0.058104828000068665,
-0.0613... |
Behavioral Interventions\nSignificant weight loss can be attained\nwith lifestyle programs that achieve a500–750 kcal/day energy de ficit, which\nin most cases is approximately 1,200 –\n1,500 kcal/day for women and 1,500 –\n1,800 kcal/day for men, adjusted for the\nindividual ’s baseline body weight. Clinical\nbenefits ty... | [
-0.0066221533343195915,
0.10152959078550339,
0.01406191661953926,
0.053394317626953125,
-0.10234460234642029,
0.005282140336930752,
-0.02139762043952942,
0.04571366310119629,
-0.07711310684680939,
-0.002789079211652279,
-0.03893362730741501,
-0.0333540141582489,
-0.029270155355334282,
-0.0... |
benefits typically begin upon achieving 5%\nweight loss (19,54), and the bene fits of\nweight loss are progressive; more inten-sive weight loss goals ( >7%,>10%,\n>15%, etc.) may be pursued to achieve\nfurther health improvements if the indi-vidual is motivated and more intensivegoals can be feasibly and safely attained. | [
0.05369798094034195,
0.03278167545795441,
-0.01815190725028515,
0.005530226044356823,
-0.015753498300909996,
0.0396680049598217,
-0.02934388257563114,
0.07756564021110535,
-0.04676409438252449,
-0.01583428494632244,
-0.009994255378842354,
0.002849346259608865,
-0.020778486505150795,
-0.013... |
Nutrition interventions may differ by\nmacronutrient goals and food choices aslong as they create the necessary energydeficit to promote weight loss (19,55 –57).\nUsing meal replacement plans prescribed\nby trained practitioners, with close moni-\ntoring, can be bene ficial. Within the inten- | [
-0.027273941785097122,
0.056780945509672165,
0.00235474924556911,
0.032459937036037445,
-0.016097502782940865,
0.011849070899188519,
-0.058544453233480453,
0.01894284412264824,
-0.04709753394126892,
-0.11297331750392914,
0.010284113697707653,
-0.025258459150791168,
-0.017076672986149788,
-... |
toring, can be bene ficial. Within the inten-\nsive lifestyle intervention group of theLook AHEAD trial, for example, the use of\na partial meal replacement plan was asso-\nciated with improvements in nutritionquality and weight loss (54), and improve-ment in cardiovascular risk factors (41). In\na systematic review and... | [
0.023154469206929207,
0.0867772176861763,
0.01885358802974224,
0.025806032121181488,
-0.02522212080657482,
0.03582461550831795,
-0.06811589002609253,
0.06393475085496902,
-0.06334014236927032,
-0.012648236937820911,
-0.005231082905083895,
0.009800812229514122,
-0.05409178137779236,
-0.0694... |
a systematic review and meta-analysis, ef-\nficacy and safety of meal replacements\n(partial or total meal replacement) as com-pared with conventional diets showed im-provements in A1C, FBG, body weight,\nand BMI (58). The nutrition choice should\nbe based on the individual ’s health status | [
0.03253980353474617,
0.04257834702730179,
-0.012361224740743637,
0.0049351840279996395,
-0.02441210113465786,
0.0028379352297633886,
0.005180229898542166,
0.06866199523210526,
-0.0426798090338707,
-0.016286037862300873,
0.007224581204354763,
-0.042224034667015076,
-0.06571751832962036,
-0.... |
be based on the individual ’s health status\nand preferences, including a determina-tion of food availability and other cultural\ncircumstances that could affect nutrition\npatterns (59).\nProven intensive behavioral interventions\nincluded $16 sessions during an initial\n6 months and focus on nutritional changes, | [
0.052065808326005936,
0.11379138380289078,
-0.02461131662130356,
0.057860761880874634,
-0.09905639290809631,
0.10524161159992218,
-0.015671325847506523,
0.052631720900535583,
-0.12585480511188507,
-0.038742419332265854,
0.03259161859750748,
-0.04485956206917763,
-0.04641260206699371,
-0.05... |
6 months and focus on nutritional changes,\nphysical activity, and behavioral strategies\nto achieve an /C24500– 750 kcal/day energy\ndeficit. Such interventions should be pro-\nvided by trained individuals and can be\nconducted in either individual or group\nsessions (54). Assessing a person ’sm o t i - | [
-0.003760649124160409,
0.07008793950080872,
-0.009993722662329674,
0.09066328406333923,
-0.07108256220817566,
0.04202619194984436,
-0.029464736580848694,
0.04064987227320671,
-0.10217179358005524,
-0.041969530284404755,
-0.006946098990738392,
-0.03250325843691826,
-0.08356957137584686,
-0.... |
sessions (54). Assessing a person ’sm o t i -\nvation level, life circumstances, and will-ingness to implement behavioral changes\nto achieve weight loss should be consid-\nered along with medical status whensuch interventions are recommendedand initiated (38,60). If such intensive be-havioral interventions are not ava... | [
0.0035178018733859062,
0.13966569304466248,
-0.028649618849158287,
0.023287348449230194,
-0.056421369314193726,
0.10056524723768234,
0.030286308377981186,
0.07915784418582916,
-0.05441095679998398,
-0.014321507886052132,
-0.0073506999760866165,
-0.0028801620937883854,
-0.015514872968196869,
... |
accessible, structured programs deliver-\ning behavioral counseling (face-to-face orremote) can be considered; however,their effectiveness varies (61,62).\nPeople with type 2 diabetes and over-\nweight or obesity who have lost weightshould be offered long-term ( $1 year)diabetesjournals.org/care Obesity and Weight Mana... | [
-0.017214259132742882,
0.05642927065491676,
-0.039343465119600296,
0.08026675879955292,
-0.09816739708185196,
0.051053594797849655,
-0.022355448454618454,
0.0024177036248147488,
-0.07555385679006577,
-0.017273416742682457,
-0.026841316372156143,
0.04005874693393707,
-0.03202783316373825,
0... |
©AmericanDiabetesAssociation | [
0.06342031806707382,
-0.04462772607803345,
-0.07223597913980484,
0.043682683259248734,
-0.045854225754737854,
-0.0014199750730767846,
-0.005912777967751026,
-0.07833275198936462,
-0.04720243066549301,
0.09212949872016907,
0.0628901943564415,
-0.04908110201358795,
0.0067015099339187145,
0.0... |
comprehensive weight loss maintenance\nprograms that provide at least monthlycontact with trained individuals and focuso no n g o i n gm o n i t o r i n go fb o d yw e i g h t(weekly or more frequently) and/or other\nself-monitoring strategies such as tracking | [
-0.01716921105980873,
-0.019736118614673615,
0.009762580506503582,
0.0005494971992447972,
-0.012454044073820114,
0.018186677247285843,
0.012431002222001553,
0.013809266500175,
-0.09668586403131485,
-0.04913335293531418,
0.010377276688814163,
-0.03167912736535072,
-0.07367505133152008,
-0.0... |
self-monitoring strategies such as tracking\nintake, steps, etc.; continued focus on nu-trition and behavioral changes; and par-ticipation in high levels of physical activity\n(200–300 min/week) (63,64). Some com-\nmercial and proprietary weight loss pro-\ngrams have shown promising weight lossresults; however, results... | [
-0.012559503316879272,
0.01079491339623928,
-0.01654479093849659,
0.017494218423962593,
0.011092960834503174,
0.049736276268959045,
0.01791047491133213,
0.047846097499132156,
-0.04350978881120682,
-0.005190398544073105,
-0.0060472325421869755,
-0.06474073231220245,
-0.01199323870241642,
-0... |
programs, most lack evidence of effec-\ntiveness, many do not satisfy guidelinerecommendations, and some promoteunscienti fic and possibly dangerous prac-\ntices (65,66).\nStructured, very-low-calorie meals, typ-\nically 800 –1,000 kcal/day, utilizing high- | [
0.00499030202627182,
0.02698451839387417,
0.022440876811742783,
0.05361657962203026,
-0.07875405997037888,
-0.008790111169219017,
0.012084189802408218,
0.0725569948554039,
-0.05304308608174324,
-0.01202877052128315,
0.006665544118732214,
-0.023369889706373215,
-0.01529975701123476,
-0.0517... |
ically 800 –1,000 kcal/day, utilizing high-\nprotein foods and meal replacementproducts, may increase the pace and/ormagnitude of initial weight loss and glyce-\nmic improvements compared with stan-\ndard behavioral interventions (20,21).However, such an intensive nutritional in-tervention should be provided only by | [
-0.03474665805697441,
-0.0020447862334549427,
-0.01676364615559578,
0.05968036502599716,
-0.024702163413167,
0.0177445150911808,
0.01400516927242279,
0.10907156765460968,
-0.050381723791360855,
-0.07421913743019104,
-0.031581081449985504,
-0.003998948726803064,
-0.04368409886956215,
-0.074... |
trained practitioners in medical settings\nwith close ongoing monitoring and in-tegration with behavioral support andcounseling, and only for short term (gen-\nerally up to 3 months). Furthermore, due | [
0.009413405321538448,
0.0017091153422370553,
-0.0013415039284154773,
0.033896852284669876,
-0.04051584377884865,
0.014102892950177193,
-0.05832187086343765,
0.040962837636470795,
-0.053368985652923584,
-0.023055072873830795,
0.0030353309120982885,
0.0144167086109519,
-0.06261541694402695,
... |
erally up to 3 months). Furthermore, due\nto the high risk of complications (electro-lyte abnormalities, severe fatigue, cardiacarrhythmias, etc.), such intensive inter-vention should be prescribed only to\ncarefully selected individuals, such as | [
0.03125656396150589,
-0.01632808893918991,
-0.019014697521924973,
0.005388020537793636,
-0.035890236496925354,
-0.07944761961698532,
-0.105237677693367,
0.10772109031677246,
-0.014961345121264458,
-0.05476801469922066,
0.042223744094371796,
0.05314455181360245,
0.012321200221776962,
0.0623... |
carefully selected individuals, such as\nthose requiring weight loss and/or gly-cemic management before a neededsurgery, if the bene fits exceed the po-\ntential risks (67 –69). As weight recur-\nrence is common, such interventionsshould include long-term, comprehen-sive weight maintenance strategies and\ncounseling to ... | [
-0.005365101154893637,
0.051995713263750076,
0.030047593638300896,
0.05264277756214142,
-0.12054867297410965,
0.024478081613779068,
-0.00835250224918127,
0.05820370092988014,
-0.09636848419904709,
-0.060051895678043365,
0.0717688649892807,
-0.0191050935536623,
-0.027006538584828377,
-0.029... |
counseling to maintain weight loss and be-\nhavioral changes (70,71).\nDespite widespread marketing and ex-\norbitant claims, there is no clear evidencethat nutrition supplements (such as herbs\nand botanicals, high-dose vitamins and | [
-0.002375323325395584,
0.020070265978574753,
-0.030458372086286545,
0.09093194454908371,
-0.010535807348787785,
0.07926702499389648,
-0.026174696162343025,
0.034751877188682556,
-0.0629873126745224,
-0.03847068175673485,
-0.01971498131752014,
-0.013919340446591377,
-0.021592913195490837,
-... |
and botanicals, high-dose vitamins and\nm i n e r a l s ,a m i n oa c i d s ,e n z y m e s ,a n t i o x i -dants, etc.) are effective for obesity man-agement or weight loss (72 –75). Several\nlarge systematic reviews show that most\ntrials evaluating nutrition supplements | [
0.011229202151298523,
0.010329725220799446,
-0.04976504668593407,
0.029893388971686363,
-0.011693823151290417,
0.0475081130862236,
0.002357210498303175,
0.04561259597539902,
-0.07248878479003906,
-0.01670927368104458,
0.016516948118805885,
0.051149941980838776,
-0.02720324881374836,
-0.043... |
trials evaluating nutrition supplements\nfor weight loss are of low quality and athigh risk for bias. High-quality publishedstudies show little or no weight loss bene-\nfits. In contrast, vitamin/mineral (e.g., iron,\nvitamin B12, vitamin D) supplementationmay be indicated in cases of documented\ndeficiency (76), and pro... | [
-0.019165020436048508,
0.020959768444299698,
-0.048031941056251526,
0.023073431104421616,
0.02937380224466324,
0.027167614549398422,
-0.018216636031866074,
0.07965296506881714,
-0.009715369902551174,
-0.025733856484293938,
-0.05651663988828659,
0.029747961089015007,
0.04333719238638878,
-0... |
deficiency (76), and protein supplements\nmay be indicated as adjuncts to medicallysupervised weight loss therapies (77,78).\nHealth disparities adversely affect peo- | [
0.0008050507749430835,
0.0016581915551796556,
0.002713626017794013,
0.009283769875764847,
-0.035537607967853546,
0.013715830631554127,
0.044683266431093216,
0.13905203342437744,
-0.055192530155181885,
-0.05982605740427971,
0.014914176426827908,
0.025452543050050735,
-0.024950524792075157,
... |
Health disparities adversely affect peo-\nple who have systematically experiencedgreater obstacles to health based on theirrace or ethnicity, socioeconomic status,gender, disability, or other factors. Over-whelming research shows that these dis-parities may signifi cantly affect health | [
0.06451352685689926,
0.09323666989803314,
0.06416186690330505,
0.022138703614473343,
-0.04473070055246353,
0.01167389564216137,
0.040225546807050705,
0.03648652136325836,
-0.10878219455480576,
-0.021285774186253548,
0.040115199983119965,
-0.01862897165119648,
-0.04512132331728935,
-0.04658... |
outcomes, including increasing the riskfor obesity, diabetes, and diabetes-relatedcomplications. Health care professionalsshould evaluate systemic, structural, andsocioeconomic factors that may impactfood choices, access to healthful foods,and nutrition patterns; behavioral pat-terns, such as neighborhood safety andava... | [
0.03627881780266762,
0.04580715671181679,
0.009929346852004528,
0.08579640090465546,
0.02200394868850708,
0.04268357530236244,
-0.011973610147833824,
0.023929661139845848,
-0.03759411349892616,
-0.05741154029965401,
0.04675139859318733,
0.019655542448163033,
-0.08845312148332596,
-0.043947... |
such as neighborhood safety andavailability of safe outdoor spaces forphysical activity; environmental exposures;access to health care; social contexts; and, | [
0.10944783687591553,
-0.00791983027011156,
0.009487098082900047,
0.008584604598581791,
0.08235073834657669,
0.02941596694290638,
0.018601931631565094,
0.0013048996916040778,
-0.08435334265232086,
0.010026795789599419,
0.10189294815063477,
-0.01920485682785511,
0.01926308497786522,
0.031152... |
ultimately, diabetes risk and outcomes.\nFor a detailed discussion of social determi-nants of health, refer to “Social Determi-\nnants of Health: A Scienti ficR e v i e w ”(79).\nPHARMACOTHERAPY\nRecommendations\n8.14 Whenever possible, minimize\nmedications for comorbid conditions\nthat are associated with weight gain.... | [
-0.00027771227178163826,
0.07658324390649796,
-0.07243051379919052,
0.08533494174480438,
-0.035179782658815384,
0.06154266372323036,
0.07698551565408707,
0.035433754324913025,
-0.07000338286161423,
-0.03437502682209015,
0.04628165066242218,
0.02719971537590027,
-0.027015144005417824,
-0.07... |
that are associated with weight gain. E\n8.15 When choosing glucose-lowering\nmedications for people with type 2diabetes and overweight or obesity,\nprioritize medications with bene ficial\neffect on weight. B\n8.16 Obesity pharmacotherapy should\nbe considered for people with diabetes\nand overweight or obesity along w... | [
-0.032134778797626495,
0.06329575181007385,
-0.0008212363463826478,
0.041944753378629684,
-0.03327448293566704,
0.022724617272615433,
0.0931447297334671,
0.13970792293548584,
-0.050744518637657166,
0.011261441744863987,
-0.014088158495724201,
0.023038815706968307,
-0.07573682069778442,
-0.... |
and overweight or obesity along with\nlifestyle changes. Potential bene fits and\nrisks must be considered. A\n8.17 In people with diabetes and over-\nweight or obesity, the preferred phar-\nmacotherapy should be a glucagon-likepeptide 1 receptor agonist or dual glucose-\ndependent insulinotropic polypeptide | [
-0.04849899187684059,
0.019026532769203186,
-0.06798984855413437,
0.022371212020516396,
-0.04710188880562782,
-0.010631313547492027,
0.05234174802899361,
0.08722015470266342,
-0.01820707507431507,
0.01839345693588257,
0.00792639795690775,
0.04939502850174904,
-0.10597804188728333,
0.057752... |
dependent insulinotropic polypeptide\nand glucagon-like peptide 1 receptoragonist with greater weight loss ef fi-\ncacy (i.e., semaglutide or tirzepatide),especially considering their added\nweight-independent bene fits (e.g.,\nglycemic and cardiometabolic). A\n8.18 To prevent therapeutic inertia,\nfor those not reaching... | [
-0.028102872893214226,
-0.03652838245034218,
-0.10275500267744064,
0.05782526731491089,
-0.03992133215069771,
0.03588439151644707,
0.09611673653125763,
0.08956276625394821,
0.019160566851496696,
-0.009311062283813953,
0.0023448090068995953,
0.03520280122756958,
-0.003798281541094184,
-0.00... |
for those not reaching goals, reevalu-\nate weight management therapiesand intensify treatment with addi-\ntional approaches (e.g., metabolicsurgery, additional pharmacologic\nagents, and structured lifestyle man-agement programs). A\nGlucose-Lowering Therapy\nNumerous effective glucose-lowering medi- | [
-0.0790950283408165,
0.07117567956447601,
-0.022012600675225258,
0.04793280363082886,
-0.07974269986152649,
0.030371559783816338,
-0.009258688427507877,
0.07752007246017456,
-0.0724891945719719,
-0.03429751470685005,
-0.018407560884952545,
0.04807620123028755,
-0.04904406517744064,
-0.0005... |
Glucose-Lowering Therapy\nNumerous effective glucose-lowering medi-\ncations are currently available. However, toachieve both glycemic and weight manage-\nment goals for diabetes treatment, health\ncare professionals should prioritize the useof glucose-lowering medications with a ben-eficial effect on weight. Agents ass... | [
-0.014040002599358559,
0.07425083220005035,
-0.030642962083220482,
0.021614301949739456,
-0.100262850522995,
0.0299160648137331,
0.00881768949329853,
0.10280924290418625,
-0.03750356286764145,
-0.0035512084141373634,
-0.06368320435285568,
0.06895839422941208,
-0.05635475367307663,
-0.00571... |
with clinically meaningful weight loss in-\nclude glucagon-like peptide 1 (GLP-1) re-\nceptor agonists, dual glucose-dependentinsulinotropic polypeptide (GIP) and GLP-1receptor agonist (tirzepatide), sodium –\nglucose cotransporter 2 inhibitors, metfor- | [
-0.023402052000164986,
-0.010809800587594509,
-0.07697077840566635,
0.06333974748849869,
-0.045583147555589676,
0.035695772618055344,
-0.022322261705994606,
0.0783543512225151,
0.05242706090211868,
-0.029610684141516685,
-0.018079424276947975,
0.03161041438579559,
-0.04947039484977722,
0.0... |
glucose cotransporter 2 inhibitors, metfor-\nmin, and amylin mimetics. Dipeptidyl pepti-dase 4 inhibitors, centrally acting dopamineagonist (bromocriptine), a-glucosidase in-\nhibitors, and bile acid sequestrants (colese-\nvelam) are considered weight neutral. In | [
-0.028879771009087563,
-0.06624026596546173,
-0.09895586222410202,
0.04264567419886589,
-0.017025113105773926,
0.019507823511958122,
0.009835822507739067,
0.1425328403711319,
0.04428205266594887,
0.0026644158642739058,
-0.009351380169391632,
-0.04290582612156868,
-0.050662923604249954,
0.0... |
velam) are considered weight neutral. In\ncontrast, insulin secretagogues (sulfonylur-eas and meglitinides), thiazolidinediones,and insulin are often associated with weightgain (see Section 9, “Pharmacologic\nApproaches to Glycemic Treatment ”).\nConcomitant Medications\nHealth care professionals should carefully | [
-0.04732661321759224,
-0.03300781548023224,
-0.09856609255075455,
0.06722533702850342,
-0.07382231205701828,
-0.042103324085474014,
0.08025546371936798,
0.12030962854623795,
-0.04816834256052971,
-0.014908034354448318,
-0.0017133156070485711,
-0.007571033667773008,
-0.055625781416893005,
0... |
Concomitant Medications\nHealth care professionals should carefully\nreview the individual ’s concomitant medi-\ncations and, whenever possible, minimize\nor provide alternatives for medications\nthat promote weight gain. Examples of | [
-0.005910457111895084,
0.035157352685928345,
-0.007129489444196224,
0.032464463263750076,
-0.08213994652032852,
0.02864558808505535,
0.057673174887895584,
0.10822807997465134,
-0.046282634139060974,
-0.049270812422037125,
-0.011638096533715725,
-0.009514696896076202,
-0.01797175221145153,
... |
that promote weight gain. Examples of\nmedications associated with weight gaininclude antipsychotics (e.g., clozapine,olanzapine, risperidone), some antide-pressants (e.g., tricyclic antidepressants,\nsome selective serotonin reuptake inhibi- | [
0.013255363330245018,
0.018409227952361107,
0.028897875919938087,
0.06670863181352615,
-0.028889978304505348,
0.028860047459602356,
0.04951052740216255,
0.08469913899898529,
0.013311696238815784,
-0.00912087969481945,
-0.004595252685248852,
0.019384074956178665,
-0.006294874474406242,
-0.0... |
some selective serotonin reuptake inhibi-\ntors, and monoamine oxidase inhibitors),glucocorticoids, injectable progestins, someanticonvulsants (e.g., gabapentin and pre-gabalin), b-blockers, and possibly sedating\nantihistamines and anticholinergics (80).\nApproved Obesity Pharmacotherapy | [
-0.014443356543779373,
-0.004708216991275549,
-0.003201523097231984,
0.08292750269174576,
-0.040500741451978683,
0.07781868427991867,
-0.007853266783058643,
0.06615903228521347,
-0.008476046845316887,
0.03937453031539917,
-0.030842753127217293,
0.024723945185542107,
-0.034144338220357895,
... |
Approved Obesity Pharmacotherapy\nThe U.S. Food and Drug Administration(FDA) has approved several medications forweight management as adjuncts to reducedcalorie diet and increased physical activity\nin individuals with a BMI $30 kg/m\n2or\n$27 kg/m2w i t ho n eo rm o r eo b e s i t y -\nassociated comorbid conditions (... | [
-0.0032458999194204807,
0.03989475965499878,
-0.009930518455803394,
0.0709618404507637,
-0.06559109687805176,
0.027170157060027122,
0.011042952537536621,
0.08635779470205307,
-0.061489854007959366,
0.01513910572975874,
-0.008038429543375969,
-0.0081713842228055,
-0.005289431195706129,
0.00... |
associated comorbid conditions (e.g., type 2\ndiabetes, hypertension, and/or dyslipide-mia). Nearly all FDA-approved obesity\nmedications have been shown to improve\nglycemia in people with type 2 diabetesS148 Obesity and Weight Management for Type 2 Diabetes Diabetes Care Volume 47, Supplement 1, January 2024\n©Americ... | [
0.026552580296993256,
0.03786159306764603,
-0.024501007050275803,
0.09477424621582031,
0.02055724523961544,
0.02366713248193264,
0.008963583037257195,
0.054303303360939026,
-0.0665401965379715,
-0.05971533805131912,
-0.013975310139358044,
0.042093150317668915,
-0.029278874397277832,
-0.035... |
and delay progression to type 2 diabetes\nin at-risk individuals (22), and some ofthese agents (e.g., liraglutide and sema-glutide) have an indication for glucoselowering as well as weight management.\nPhentermine and other older adrenergic\nagents are approved for short-term treat-ment (#12 weeks) (81), while all othe... | [
0.013424905948340893,
0.00392695190384984,
-0.03761601820588112,
0.029637454077601433,
-0.014088431373238564,
0.016331659629940987,
0.02224447764456272,
0.05549394339323044,
-0.06522362679243088,
-0.019983718171715736,
0.005475935991853476,
0.05013463273644447,
-0.0969163179397583,
0.01061... |
are approved for long-term treatment\n(>12 weeks) (22) ( Table 8.1 ). (Refer to\nSection 14, “Children and Adolescents, ”\nfor medications approved for adolescents\nwith obesity.) In addition, setmelanotide,\na melanocortin 4 receptor agonist, is ap- | [
0.0030780653469264507,
0.07185595482587814,
0.02228296361863613,
0.030105214565992355,
-0.031416647136211395,
0.047075819224119186,
-0.06628527492284775,
0.07667110115289688,
-0.08016877621412277,
0.00883410219103098,
0.02162071317434311,
0.06600499898195267,
-0.07694853097200394,
0.049659... |
a melanocortin 4 receptor agonist, is ap-\nproved for use in cases of rare geneticmutations resulting in severe hyperphagiaand extreme obesity, such as leptin recep-tor de ficiency and proopiomelanocortin\ndeficiency.\nIn people with type 2 diabetes and | [
-0.03164026886224747,
0.023457519710063934,
-0.029797744005918503,
0.04718353971838951,
-0.05189350247383118,
0.0808975100517273,
0.03075416572391987,
0.11027301847934723,
-0.04928959161043167,
0.04031844437122345,
-0.015024205669760704,
0.028095152229070663,
-0.10155867040157318,
0.010704... |
deficiency.\nIn people with type 2 diabetes and\noverweight or obesity, agents with bothglucose-lowering and weight loss ef-fects are preferred (refer to Section 9,\n“Pharmacologic Approaches to Diabetes\nTreatment ”), which include agents from\nthe GLP-1 receptor agonist class and the\ndual GIP and GLP-1 receptor agoni... | [
0.002118045696988702,
-0.0366249717772007,
-0.05241577327251434,
0.06921407580375671,
-0.09373558312654495,
-0.026064207777380943,
0.0177781879901886,
0.11875510960817337,
-0.024412231519818306,
-0.017145028337836266,
0.021946536377072334,
0.0711297020316124,
-0.09768323600292206,
0.003991... |
dual GIP and GLP-1 receptor agonist\nclass. Should use of these medications\nnot result in achievement of weightmanagement goals, or if they are not tol-erated or contraindicated, other obesity\ntreatment approaches should be consid- | [
-0.0023538186214864254,
-0.0023436385672539473,
-0.04248534142971039,
0.0197864081710577,
-0.11792413145303726,
-0.0037531270645558834,
0.022104423493146896,
0.055339377373456955,
-0.02874830737709999,
-0.018570849671959877,
0.022886959835886955,
0.006623034365475178,
-0.07385841757059097,
... |
treatment approaches should be consid-\nered. Two phase 3 trials have demon-strated the potential for use of the dualGIP and GLP-1 receptor agonist (tirzepa-tide) for obesity (SURMOUNT-1, individuals\nwith obesity, and SURMOUNT-2, individuals | [
-0.016269873827695847,
0.010399063117802143,
-0.08746811747550964,
0.00989103689789772,
-0.060010917484760284,
0.0344209261238575,
-0.06447161734104156,
0.0542263388633728,
-0.015059662982821465,
-0.02156692184507847,
0.04734155908226967,
0.013308833353221416,
-0.059695132076740265,
0.0162... |
with obesity, and SURMOUNT-2, individuals\nwith obesity and type 2 diabetes) (82,83).In the SURMOUNT-2 trial, tirzepatide re-sulted in body weight loss of 9.6% and\n11.6% more than placebo and A1C lower-\ning of 1.55% and 1.57% more than placeboafter 72 weeks of treatment with the 10mg and 15 mg doses, respectively, wi... | [
0.0421878844499588,
-0.0007002837373875082,
-0.06061818078160286,
0.10483193397521973,
-0.06633798032999039,
0.017506388947367668,
0.0069465008564293385,
0.1332317739725113,
-0.0009914964903146029,
-0.03266414999961853,
-0.01507406122982502,
0.045794375240802765,
0.01703043282032013,
0.027... |
adverse effects similar to those seen with\nthe GLP-1 receptor agonist class (83).\nHealth care professionals should be\nknowledgeable about the bene fits, dosing,\nand risks for each treatment option to bal-\nance the potential benefi ts of successful\nweight loss against the potential risks for | [
0.011488685384392738,
-0.005526204593479633,
-0.03949223831295967,
0.016777832061052322,
-0.09609688073396683,
-0.0003732909099198878,
0.007831599563360214,
0.17941643297672272,
-0.06427101045846939,
-0.023726722225546837,
0.008682535961270332,
0.04738599434494972,
-0.06295178830623627,
0.... |
weight loss against the potential risks for\neach individual. The high risk and preva-lence of cardiovascular disease in peoplewith diabetes has to be balanced against\nthe lack of long-term cardiovascular out-\ncomes trial data for agents like naltrexone-bupropion and phentermine-topiramate.All these medications are c... | [
0.012697063386440277,
0.06943100690841675,
-0.02676972560584545,
0.04521544277667999,
-0.011941799893975258,
0.059560347348451614,
-0.041495732963085175,
0.13957689702510834,
-0.024419376626610756,
-0.007123381830751896,
-0.08284112811088562,
0.023123281076550484,
-0.008318583481013775,
-0... |
in individuals who are pregnant or actively\ntrying to conceive and are not recommendedfor use in individuals who are nursing. Indi-\nviduals of childbearing potential shouldreceive counseling regarding the use ofreliable methods of contraception. Ofnote, while weight loss medications are\no f t e nu s e di np e o p l ... | [
-0.05530443415045738,
0.010479075834155083,
-0.07231749594211578,
0.015676064416766167,
0.003191200317814946,
0.0752188041806221,
0.04740799590945244,
0.12247702479362488,
0.0009504396002739668,
0.030362624675035477,
0.012847669422626495,
0.07790737599134445,
-0.0662815049290657,
0.0127292... |
o f t e nu s e di np e o p l ew i t ht y p e1d i a b e -\ntes, clinical trial data in this populationare limited.\nAssessing Efficacy and Safety of\nObesity Pharmacotherapy\nUpon initiating medications for obesity,\nassess their ef ficacy and safety at least\nmonthly for the first 3 months and at\nleast quarterly thereaf... | [
0.016218120232224464,
-0.016373194754123688,
-0.060594502836465836,
-0.007249202113598585,
0.020390145480632782,
0.03802330419421196,
-0.05650351569056511,
0.12966810166835785,
-0.004823732655495405,
-0.0049723065458238125,
0.030067062005400658,
0.00857760664075613,
0.01021541003137827,
0.... |
least quarterly thereafter. Modeling from\npublished clinical trials consistently shows\nthat early responders have improvedlong-term outcomes (84,85); however, itis notable that the response rate with thelatest generation of obesity pharmaco-\ntherapies is much higher (48,83). Unless | [
0.038853973150253296,
0.010659638792276382,
-0.011154883541166782,
0.06682717055082321,
-0.009996953420341015,
0.0163191556930542,
-0.13706989586353302,
0.13627491891384125,
0.023265618830919266,
-0.013604946434497833,
0.016184408217668533,
0.03729430213570595,
-0.011203733272850513,
-0.00... |
therapies is much higher (48,83). Unless\nclinical circumstances (such as poor toler-ability) or other considerations (such as fi-\nnancial expense or individual preference)suggest otherwise, those who achieve\nsufficient early weight loss upon starting\na chronic obesity medication (typically de-\nfined as >5% weight los... | [
0.02045232243835926,
-0.01505574956536293,
-0.028338847681879997,
0.03932950273156166,
-0.036623869091272354,
0.0024189534597098827,
-0.04780084267258644,
0.16600298881530762,
-0.03974202275276184,
-0.026803838089108467,
-0.05983411520719528,
0.07746779918670654,
-0.02000129036605358,
0.01... |
fined as >5% weight loss after 3 months\nof use) should continue the medication\nlong term. When early weight loss results\nare modest (typically <5% weight loss af-\nter 3 months of use), the bene fits of on-\ngoing treatment need to be balanced in\nthe context of the glycemic response, the\navailability of other potent... | [
-0.00891935545951128,
-0.020350299775600433,
-0.027345983311533928,
0.018292834982275963,
-0.037492651492357254,
-0.033105868846178055,
-0.014934878796339035,
0.13652832806110382,
-0.033003613352775574,
-0.04503075033426285,
0.0014835462206974626,
0.03494933620095253,
-0.034779343754053116,
... |
availability of other potential treatment\noptions, treatment tolerance, and overalltreatment burden.\nOngoing monitoring of the achievement\nand maintenance of weight managementgoals is recommended. For those not reach-\ning or maintaining weight-related treatment | [
-0.04036113619804382,
0.0701623484492302,
-0.005888395942747593,
0.04335258901119232,
-0.07079549133777618,
0.037873122841119766,
-0.006030655466020107,
0.060182586312294006,
-0.09015683829784393,
-0.04385054484009743,
0.06239856779575348,
-0.00737018883228302,
-0.006509694270789623,
0.027... |
ing or maintaining weight-related treatment\ngoals, reevaluate weight management ther-apies and intensify treatment with addi-tional approaches (e.g., metabolic surgery,\nadditional pharmacologic agents, and struc-\ntured lifestyle management programs).\nMEDICAL DEVICES FOR WEIGHT\nLOSS\nWhile gastric banding devices h... | [
-0.01451845932751894,
0.015785936266183853,
-0.007421205751597881,
0.058466214686632156,
-0.09018892049789429,
-0.0020822964143007994,
0.02103690803050995,
0.09307944029569626,
-0.06652435660362244,
-0.04454934224486351,
0.028162769973278046,
0.016217811033129692,
-0.04881131276488304,
0.0... |
LOSS\nWhile gastric banding devices have fallen\nout of favor due to their limited long-term ef ficacy and high rate of complica-\ntions, several minimally invasive medicaldevices have been approved by the FDAfor short-term weight loss, including im-planted gastric balloons, a vagus nervestimulator, and gastric aspirati... | [
0.002964877290651202,
0.03647886589169502,
-0.00598467793315649,
0.05236300453543663,
-0.02901027537882328,
0.0012429201742634177,
0.04413516819477081,
0.12516731023788452,
-0.021755335852503777,
-0.03209148719906807,
-0.007767159957438707,
0.009311026893556118,
-0.0527978241443634,
-0.008... |
(86). High cost, limited insurance coverage,\nand limited data supporting the effi cacy ofthese devices in the treatment of individu-\nals with diabetes has created uncertaintyfor their current use (87).\nAn oral hydrogel (cellulose and citric\nacid) has been approved for long-termuse in those with BMI >25 kg/m\n2to | [
-0.030327480286359787,
0.02669619768857956,
0.03844612091779709,
-0.0013215031940490007,
-0.08182276785373688,
-0.0047178673557937145,
0.06639157235622406,
0.1483766734600067,
-0.04297726973891258,
-0.02307754009962082,
-0.009458605200052261,
0.029475471004843712,
-0.026450147852301598,
-0... |
2to\nsimulate the space-occupying effect ofimplantable gastric balloons. Taken withwater 30 min before meals, the hydrogelexpands to fill a portion of the stomach\nvolume to help decrease food intake dur-\ning meals. The average weight loss was | [
0.001081752241589129,
0.033514123409986496,
0.04934101551771164,
0.027409907430410385,
-0.054260365664958954,
-0.04144078865647316,
0.05512451380491257,
0.07113471627235413,
-0.026686642318964005,
-0.04923689365386963,
0.018008893355727196,
-0.04051024466753006,
-0.012247774749994278,
0.00... |
ing meals. The average weight loss was\nrelatively small (2.1% greater than pla-cebo), and very few participants had dia-betes at baseline ( /C2410%) (88).\nMETABOLIC SURGERY\nRecommendations\n8.19 Consider metabolic surgery as a\nweight and glycemic management ap-\nproach in people with diabetes with\nBMI$30.0 kg/m2(o... | [
0.0075654820539057255,
0.11364491283893585,
-0.010455366224050522,
-0.014850670471787453,
-0.08887376636266708,
-0.048207804560661316,
0.004065553657710552,
0.0825691819190979,
0.00524902855977416,
0.008005043491721153,
-0.018850786611437798,
-0.009333529509603977,
-0.07441071420907974,
-0... |
proach in people with diabetes with\nBMI$30.0 kg/m2(or$27.5 kg/m2in\nAsian American individuals) who areotherwise good surgical candidates. A\n8.20 Metabolic surgery should be\nperformed in high-volume centerswith interprofessional teams knowl-edgeable about and experienced\nin managing obesity, diabetes, and\ngastroin... | [
-0.023532142862677574,
0.07004514336585999,
-0.013414693996310234,
0.023222964257001877,
-0.07553660869598389,
-0.057752326130867004,
0.05911358818411827,
0.05543805658817291,
-0.013607209548354149,
0.032674696296453476,
-0.025133229792118073,
-0.006344256456941366,
-0.06981242448091507,
0... |
in managing obesity, diabetes, and\ngastrointestinal surgery (www.facs\n.org/quality-programs/accreditation-\nand-veri fication/metabolic-and-bariatric-\nsurgery-accreditation-and-quality-improvement-program/). E\n8.21 People being considered for met-\nabolic surgery should be evaluated forcomorbid psychological conditi... | [
0.016094569116830826,
0.056954652070999146,
-0.044805437326431274,
0.0020324026700109243,
-0.08881824463605881,
-0.01676037162542343,
-0.00918254442512989,
0.025496706366539,
-0.08827150613069534,
-0.048062488436698914,
-0.01210329681634903,
0.03603474795818329,
-0.028554679825901985,
-0.0... |
social and situational circumstances\nthat have the potential to interfere\nwith surgery outcomes. B\n8.22 People who undergo metabolic\nsurgery should receive long-term med-\nical and behavioral support and rou-\ntine micronutrient, nutritional, and\nmetabolic status monitoring. B\n8.23 If post –metabolic surgery hypo... | [
-0.008539373986423016,
0.09469354897737503,
-0.02051827870309353,
-0.0062736086547374725,
-0.05085734277963638,
0.0022263743449002504,
-0.01423034816980362,
0.010923934169113636,
-0.08196061104536057,
-0.04249073937535286,
0.02527325041592121,
0.05861876159906387,
-0.02748986706137657,
0.0... |
8.23 If post –metabolic surgery hypogly-\ncemia is suspected, clinical evaluationshould exclude other potential disor-\nders contributing to hypoglycemia, and\nmanagement should include education,\nmedical nutrition therapy with a regis-\ntered dietitian/nutritionist experienced in\npost–metabolic surgery hypoglycemia, | [
-0.022376617416739464,
0.11431385576725006,
0.01436146255582571,
0.016179630532860756,
-0.0091455252841115,
-0.022615376859903336,
-0.012685015797615051,
0.09420624375343323,
-0.10527577996253967,
-0.05971860885620117,
-0.0011943442514166236,
-0.016586916521191597,
-0.09255656599998474,
0.... |
post–metabolic surgery hypoglycemia,\nand medication treatment, as needed.\nAContinuous glucose monitoring\nshould be considered as an importantadjunct to improve safety by alerting\nindividuals to hypoglycemia, especiallydiabetesjournals.org/care Obesity and Weight Management for Type 2 Diabetes S149\n©AmericanDiabete... | [
-0.027251476421952248,
0.09683413058519363,
-0.029924454167485237,
0.03216953203082085,
-0.04051671549677849,
-0.016888316720724106,
0.03459085151553154,
0.05086646229028702,
-0.07670286297798157,
-0.020633846521377563,
-0.03922220319509506,
0.05152638629078865,
-0.07840273529291153,
0.029... |
Table 8.1 —Obesity pharmacotherapy\nMedication name and\ntypical adult maintenance\ndoseAverage wholesale price\n(median and range for\n30-day supply) (142)National Average Drug\nAcquisition Cost\n(30-day supply) (143) Treatment armsWeight loss\n(% loss from\nbaseline)Common side effects(144–149)Possible safety concern... | [
-0.005224701017141342,
0.029045602306723595,
0.016738053411245346,
0.032217271625995636,
0.010058239102363586,
0.07829402387142181,
0.03946677967905998,
0.18414552509784698,
-0.11457659304141998,
0.02141416259109974,
-0.008107324130833149,
-0.023779762908816338,
0.03259105235338211,
-0.035... |
Short-term treatment (12 weeks)\nSympathomimetic amine anorectic\nPhentermine (150)\n8–37.5 mg q.d.* $43 ($5 –$90),\n37.5 mg/day$2(37.5 mg dose)15 mg q.d.7.5 mg q.d.Placebo5.04.91.9Dry mouth, insomnia,\ndizziness, irritability,increased blood pressure,\nelevated heart rate/C15Contraindicated for use in\ncombination wit... | [
0.053862065076828,
-0.02795281819999218,
-0.032874248921871185,
0.007930098101496696,
-0.05005770921707153,
0.029687732458114624,
-0.0016023783246055245,
0.12292375415563583,
0.0055608563125133514,
0.04856278374791145,
-0.01208776980638504,
-0.011819225735962391,
-0.004222840070724487,
0.0... |
combination with monoamineoxidase inhibitors\nLong-term treatment (52 or 56 weeks)\nLipase inhibitor\nOrlistat (4)60 mg t.i.d. (OTC)120 mg t.i.d. (Rx)$52 ($41 –$82)\n$843 ($781 –$904)NA$722120 mg t.i.d. †\nPlacebo9.65.6Abdominal pain, flatulence, | [
0.04486294835805893,
-0.009383061900734901,
0.022545455023646355,
0.04082246497273445,
-0.05189213901758194,
0.02425384148955345,
-0.025523679330945015,
0.15096792578697205,
0.042598623782396317,
0.04398181289434433,
-0.03984701260924339,
-0.00235163327306509,
0.015590154565870762,
0.05625... |
Placebo9.65.6Abdominal pain, flatulence,\nfecal urgency/C15Potential malabsorption of fat-soluble vitamins (A, D, E, K) and ofcertain medications (e.g.,\ncyclosporine, thyroid hormone,\nanticonvulsants)\n/C15Rare cases of severe liver injury\nreported\n/C15Cholelithiasis\n/C15Nephrolithiasis\nSympathomimetic amine anore... | [
-0.021211422979831696,
-0.05618807300925255,
-0.03851184621453285,
0.0019863725174218416,
-0.04216304421424866,
-0.03796444460749626,
-0.01514914445579052,
0.14442460238933563,
0.006920989137142897,
-0.028768910095095634,
-0.020126385614275932,
-0.03868214040994644,
-0.05205395072698593,
0... |
Sympathomimetic amine anorectic/antiepileptic combination\nPhentermine/topiramate ER (47)\n7.5 mg/46 mg q.d. ‡ $223(7.5 mg/46 mg dose)$179(7.5 mg/46 mgdose)15 mg/92 mg q.d. §\n7.5 mg/46 mg q.d. §\nPlacebo9.87.81.2Constipation, paresthesia,\ninsomnia, nasopharyngitis,xerostomia, increased\nblood pressure/C15Contraindica... | [
0.058204054832458496,
-0.051552172750234604,
-0.055183861404657364,
-0.005645452532917261,
-0.03705184534192085,
-0.017184285447001457,
0.09505972266197205,
0.15873682498931885,
0.02786896750330925,
0.09923435002565384,
-0.016018452122807503,
-0.02066463604569435,
-0.010959917679429054,
0.... |
blood pressure/C15Contraindicated for use in\ncombination with monoamineoxidase inhibitors\n/C15Birth defects\n/C15Cognitive impairment\n/C15Acute angle-closure glaucoma\nOpioid antagonist/antidepressant combination\nNaltrexone/bupropion ER (15)16 mg/180 mg b.i.d. $750 $599 16 mg/180 mg b.i.d.Placebo5.01.8Constipation,... | [
0.005602648016065359,
0.005855152849107981,
-0.05156485363841057,
-0.006245572119951248,
0.012792621739208698,
0.009567185305058956,
-0.025453457608819008,
0.17058435082435608,
-0.01109002809971571,
0.019643409177660942,
-0.025985443964600563,
-0.046529509127140045,
-0.06528767198324203,
-... |
headache, xerostomia,\ninsomnia, elevated heart\nrate and blood pressure/C15Contraindicated in people withunmanaged hypertension and/or\nseizure disorders\n/C15Contraindicated for use with\nchronic opioid therapy\n/C15Acute angle-closure glaucoma\nBlack box warning:/C15Risk of suicidal behavior/ideation in | [
-0.026647226884961128,
0.02506771869957447,
-0.037221480160951614,
0.06570085883140564,
0.00939065683633089,
0.0009461486479267478,
0.04500385373830795,
0.09095992892980576,
-0.04164699465036392,
-0.017714859917759895,
0.017846515402197838,
-0.04531421884894371,
-0.0015323467087000608,
0.0... |
Black box warning:/C15Risk of suicidal behavior/ideation in\npeople younger than 24 years oldwho have depression\nContinued on p. S151S150 Obesity and Weight Management for Type 2 Diabetes Diabetes Care Volume 47, Supplement 1, January 2024\n©AmericanDiabetesAssociation | [
-0.02434708923101425,
0.07046161592006683,
-0.09809837490320206,
0.09323439002037048,
0.05141042545437813,
0.06043350324034691,
0.046151310205459595,
0.11576970666646957,
-0.05140512436628342,
-0.03420964255928993,
-0.009487085975706577,
-0.01885165460407734,
-0.04501368850469589,
-0.00302... |
Table 8.1 —Continued\nMedication name and\ntypical adult maintenancedoseAverage wholesale price(median and range for30-day supply) (142)National Average DrugAcquisition Cost(30-day supply) (143) Treatment armsWeight loss(% loss frombaseline)Common side effects(144–149)Possible safety concerns andconsiderations (144–149... | [
0.017782380804419518,
0.03456982597708702,
0.024169689044356346,
-0.0008690130780451,
-0.0001532838068669662,
0.06380578875541687,
0.030876418575644493,
0.21071502566337585,
-0.12457737326622009,
0.019673913717269897,
0.01115445513278246,
-0.016492241993546486,
0.049623169004917145,
-0.009... |
Glucagon-like peptide 1 receptor agonist\nLiraglutide (16,49) jj\n3 mg q.d. $1,619 $1,294 3.0 mg q.d.\n1.8 mg q.d.Placebo6.04.72.0Gastrointestinal side effects\n(nausea, vomiting,diarrhea, esophageal\nreflux), injection site\nreactions, elevated heart | [
0.017121044918894768,
-0.06242522597312927,
-0.061813581734895706,
0.035353366285562515,
-0.06173879653215408,
-0.014941577799618244,
0.04372569918632507,
0.14385342597961426,
0.07295921444892883,
0.019569119438529015,
-0.020296689122915268,
0.01808265782892704,
-0.03409349545836449,
0.020... |
reflux), injection site\nreactions, elevated heart\nrate, hypoglycemia/C15Pancreatitis has been reported inclinical trials, but causality has notbeen established. Discontinue if\npancreatitis is suspected.\n/C15Use caution in people with kidney\ndisease when initiating or increasingdose due to potential risk of acute\nk... | [
0.006300562992691994,
0.004809112753719091,
0.01911100186407566,
-0.009423754177987576,
-0.034932274371385574,
-0.03439321741461754,
0.004043196327984333,
0.09534909576177597,
-0.012339558452367783,
0.02474578097462654,
0.007078649941831827,
0.021333105862140656,
0.01768629439175129,
0.051... |
kidney injury.\n/C15May cause cholelithiasis and gallstone-\nrelated complications.\n/C15Gastrointestinal disorders (severeconstipation and small bowel\nobstruction/ileus progression)\n/C15Monitor for potential consequences of\ndelayed absorption of oral medications.\nBlack box warning:\n/C15Risk of thyroid C-cell tumo... | [
-0.028785299509763718,
-0.01566126011312008,
0.022903140634298325,
0.011655713431537151,
-0.029231896623969078,
0.0081727784126997,
-0.017751792445778847,
0.11571613699197769,
-0.03994216397404671,
-0.03834705799818039,
-0.05902761593461037,
0.004251593258231878,
-0.05137064680457115,
-0.0... |
/C15Risk of thyroid C-cell tumors inrodents; human relevance not\ndetermined\nSemaglutide (48,151) jj\n2.4 mg once weekly $1,619 $1,295 2.4 mg weekly\n1.0 mg weekly\nPlacebo9.6\n7.0\n3.4Gastrointestinal side effects\n(nausea, vomiting,diarrhea, esophagealreflux), injection site\nreactions, elevated heart | [
-0.01140118483453989,
0.06465645879507065,
-0.02022409997880459,
-0.011116144247353077,
0.01600060425698757,
0.0422997921705246,
0.021902291104197502,
0.13304392993450165,
0.015959182754158974,
0.011224955320358276,
-0.0811459869146347,
-0.08097998797893524,
0.02659345045685768,
-0.0911770... |
reactions, elevated heart\nrate, hypoglycemia/C15Pancreatitis has been reported inclinical trials, but causality has not\nbeen established. Discontinue ifpancreatitis is suspected.\n/C15Use caution in people with kidney\ndisease when initiating or increasing\ndose due to potential risk of acutekidney injury. | [
-0.0034295159857720137,
0.01764814741909504,
0.023396672680974007,
-0.0047636451199650764,
0.013164365664124489,
-0.022703487426042557,
0.012997613288462162,
0.10331559181213379,
-0.023528164252638817,
0.050922270864248276,
0.004152047913521528,
0.000042898427636828274,
-0.019004812464118004... |
dose due to potential risk of acutekidney injury.\n/C15May cause cholelithiasis and gallstone-related complications.\n/C15Gastrointestinal disorders (severeconstipation and small bowel\nobstruction/ileus progression)\n/C15Monitor for potential consequences of\ndelayed absorption of oral medications. | [
0.027205519378185272,
-0.06135199964046478,
-0.005165286362171173,
-0.004912863951176405,
-0.03233896195888519,
-0.05218496173620224,
0.008812607266008854,
0.1435946226119995,
0.013207059353590012,
-0.048468217253685,
0.007495791185647249,
0.012434737756848335,
-0.03686647489666939,
0.0539... |
delayed absorption of oral medications.\nBlack box warning:/C15Risk of thyroid C-cell tumors in\nrodents; human relevance notdetermined\nContinued on p. S152diabetesjournals.org/care Obesity and Weight Management for Type 2 Diabetes S151\n©AmericanDiabetesAssociation | [
-0.015082476660609245,
0.039671335369348526,
-0.07235673815011978,
0.020890790969133377,
0.008828007616102695,
0.01653362810611725,
0.013886037282645702,
0.07048340886831284,
-0.030528409406542778,
-0.027780843898653984,
-0.0514841191470623,
0.03876723349094391,
-0.014231076464056969,
-0.0... |
Table 8.1 —Continued\nMedication name and\ntypical adult maintenance\ndoseAverage wholesale price\n(median and range for\n30-day supply) (142)National Average Drug\nAcquisition Cost\n(30-day supply) (143) Treatment armsWeight loss\n(% loss from\nbaseline)Common side effects(144–149)Possible safety concerns andconsidera... | [
0.0013349219225347042,
0.015993738546967506,
0.01879427395761013,
0.00318282563239336,
0.01218020636588335,
0.07809602469205856,
0.04039304703474045,
0.21143870055675507,
-0.12618747353553772,
0.01843281462788582,
0.031014064326882362,
-0.012831241823732853,
0.03010403737425804,
-0.0097291... |
Dual glucose-dependent insulinotropic polypeptide and glucagon-like peptide 1 receptor agonist\nTirzepatide (83)\n5 mg, 10 mg, or\n15 mg once weeklyNA NA 10 mg weekly15 mg weeklyPlacebo12.814.73.2Gastrointestinal side effects\n(nausea, vomiting,diarrhea, esophagealreflux), injection site | [
0.03800778463482857,
-0.03522013500332832,
-0.08195765316486359,
0.039763566106557846,
-0.03569626808166504,
-0.0361117348074913,
0.08448928594589233,
0.08577663451433182,
-0.030933838337659836,
0.004841991234570742,
-0.060669489204883575,
0.02654057927429676,
-0.041484534740448,
-0.020022... |
(nausea, vomiting,diarrhea, esophagealreflux), injection site\nreactions, elevated heartrate, hypoglycemia/C15Pancreatitis has been reported inclinical trials, but causality has notbeen established. Discontinue ifpancreatitis is suspected. | [
0.08022774755954742,
-0.02167118899524212,
-0.006136876530945301,
0.0389421321451664,
0.033724796026945114,
-0.040764495730400085,
0.04311328008770943,
0.10408513993024826,
-0.021754510700702667,
0.044325102120637894,
-0.008767051622271538,
-0.02183314599096775,
0.025220444425940514,
0.044... |
/C15Use caution in people with kidneydisease when initiating or increasingdose due to potential risk of acutekidney injury.\n/C15May cause cholelithiasis andgallstone-related complications.\n/C15Gastrointestinal disorders (severe\nconstipation and small bowel\nobstruction/ileus progression)\n/C15Monitor effects of oral... | [
-0.02628760039806366,
-0.04568753018975258,
0.040799640119075775,
-0.003989395685493946,
-0.0385887548327446,
-0.04224167391657829,
-0.02571350894868374,
0.1356412023305893,
-0.016760827973484993,
-0.051606763154268265,
0.003411324694752693,
0.013775529339909554,
-0.043648406863212585,
0.0... |
/C15Monitor effects of oral medications\nwith narrow therapeutic index\n(warfarin) or whose ef ficacy is\ndependent on threshold\nconcentration.\n/C15Advise those using oral hormonal\ncontraception to use or add a non-\noral contraception method for4 weeks after initiation and doseescalations. | [
-0.03820187970995903,
0.00653779087588191,
-0.09123615175485611,
0.010608255863189697,
0.021742943674325943,
0.0548921599984169,
-0.0021853914950042963,
0.1665593683719635,
0.008156892843544483,
0.0016739109996706247,
-0.002533484948799014,
-0.020264148712158203,
-0.0775316059589386,
0.055... |
Black box warning:/C15Risk of thyroid C-cell tumors inrodents; human relevance not\ndetermined.\nSelect safety and side effect information is provided; for a comprehensive discussion of safety considerations, please refer to the prescribing information for each agent. b.i.d., twice daily; ER, extended release; | [
-0.03058250993490219,
0.044731609523296356,
-0.08124403655529022,
-0.027675310149788857,
0.04272959381341934,
0.05371423065662384,
0.013987617567181587,
0.14040686190128326,
-0.03000243939459324,
-0.04731394350528717,
-0.0296405591070652,
-0.03146151453256607,
0.032893285155296326,
-0.0713... |
Subsets and Splits
No community queries yet
The top public SQL queries from the community will appear here once available.